Targeting Vascular Endothelial Growth Factor (VEGF)

Robert Vitti Robert Vitti, M.D., M.B.A. VP Clinical Sciences Ophthalmology

Clinical Trials

Regeneron has investigational product candidates progressing through all stages of human clinical trials.

See if there are clinical trials that might be right for you

Regeneron is evaluating a potential treatment for vision-threatening eye diseases characterized by the growth of abnormal blood vessels and leakage of fluid behind the macula, the central portion of the retina that is responsible for central vision.

The Regeneron program targets vascular endothelial growth factor (VEGF). While the VEGF protein stimulates the formation of blood vessels that are necessary to supply nutrients to tissues, excessive VEGF production is a major contributing factor in a number of diseases including diseases of the retina. In these conditions, blood vessels become fragile, and fluid and blood can leak into surrounding tissues, causing vision-threatening swelling in the area of the macula. If untreated, the swelling can damage the cells of the macula, create blind spots in central vision, and lead to permanent vision loss.

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)